Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Profile
Team
Investment Practice
Portfolio
FAQ
Download Area
News
Events
Contact Us
Text size

GLSV news

01.02.2013 Global Life Science Ventures: 2012 Review more...

30.01.2012 Global Life Science Ventures: 2011 Review more...

24.01.2011 Global Life Science Ventures: 2010 Review more...

14.01.2010 Global Life Science Ventures: 2009 Review more...

13.02.2009 Global Life Science Ventures: 2008 highlights more...

More News


Portfolio company news

18.04.2013 Pieris Achieves Second Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin® Therapeutics more...

16.04.2013 Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines more...

10.04.2013 Pieris and Sanofi Broaden Existing Collaboration more...

27.03.2013 Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S’ Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials more...

11.02.2013 Horizon Pharma Announces Preliminary Fourth Quarter and Full Year 2012 Revenues, Full U.S. Commercial Launch of RAYOS(R) (Prednisone) Delayed-Release Tablets and Approval of LODOTRA(R) in South Korea more...

More News